

LivaNova

First-Quarter 2025 Earnings Update

May 7, 2025



Safe Harbor

Certain statements in this material, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events, and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, forward-looking statements can be identified by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this material, and include, but are not limited to, the following risks and uncertainties: volatility in the global market and worldwide economic conditions, including as caused by the invasion of Ukraine, the evolving instability in the Middle East, inflation, changing interest rates, foreign exchange fluctuations, and changes to existing trade agreements and relationships between the U.S. and other countries, including the implementation of tariffs, trade restrictions, and sanctions; adverse changes in export and import costs and other trade restrictions as well as uncertainty over global tariffs; risks relating to supply chain pressures; cybersecurity incidents or other disruptions to the Company’s information technology systems or those of third parties with which the Company interacts; costs of complying with privacy and security of personal information requirements and laws; changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies; failure of R&D investments or investment collaborations to be successful; failure to maintain appropriate working relationships with healthcare professionals to aid in the continuing development of products; the risk of quality issues and the impacts thereof; risks relating to recalls, replacement of inventory, enforcement actions, or product liability claims; failure to comply with, or changes in, laws, regulations, or administrative practices affecting government regulation of the Company’s products; failure to retain key personnel, succession plan, and negotiate with local works councils; failure to obtain approvals or reimbursement in relation to the Company’s products; unfavorable results from clinical studies or failure to meet milestones; pending or existing climate change; global healthcare policy changes that may lead to restricted access and pricing as well as payback requirements and limited reimbursement; changes or reduction in reimbursement for the Company’s products or failure to comply with rules relating to reimbursement of healthcare goods and services; failure to comply with rules relating to healthcare goods and services as well as anti-bribery laws; product liability, intellectual property, shareholder-related, environmental-related, income tax, and other litigation, disputes, losses, and costs, including in the case of the Company’s 3T Heater-Cooler litigation; risks associated with environmental laws and regulations as well as environmental liabilities, violations, and litigation, including in the case of Saluggia and SNIA; failure to protect the Company’s proprietary intellectual property; risks relating to the Company’s indebtedness; failure of divestitures and/or new acquisitions to further the Company’s strategic objectives or strengthen the Company’s existing businesses; the potential for impairments of intangible assets, goodwill, and other long-lived assets; changes in tax laws and regulations, including exposure to additional income tax liabilities; effectiveness of the Company’s internal controls over financial reporting; changes in the Company’s profitability and/or failure to manage costs and expenses; fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates; and other unknown or unpredictable factors that could harm the Company’s financial performance.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

Readers are cautioned not to place undue reliance on the Company’s forward-looking statements, which speak only as of the date of this material. The Company undertakes no obligation to update publicly any of the forward-looking statements in this material to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If LivaNova updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.

Intellectual Property, Trademarks and Trade Names

This material may contain references to LivaNova's proprietary intellectual property, including among others:

- Trademarks for LivaNova's Neuromodulation systems, the VNS Therapy™ System, and LivaNova's proprietary pulse generator products: Model 102 (Pulse™), Model 102R (Pulse Duo™), Model 103 (Demipulse™), Model 104 (Demipulse Duo™), Model 106 (AspireSR™), Model 1000 (SenTiva™), Model 1000-D (SenTiva™ Duo), and Model 8103 (Symmetry™).
- Trademarks for LivaNova's Cardiopulmonary products and systems: Essenz™, S5™, S5 Pro™, B-Capta™, Inspire™, Heartlink™, XTRA™, 3T Heater-Cooler™, Connect™, and Revolution™.
- Trademarks for LivaNova's advanced circulatory support systems: TandemLife™, TandemHeart™, TandemLung™, ProtekDuo™, LifeSPARC™, ALung™, Hemolung™, Respiratory Dialysis™, and ActivMix™.
- Trademarks for LivaNova's obstructive sleep apnea system: ImThera™ and aura6000™.

These trademarks and trade names are the property of LivaNova or the property of LivaNova's consolidated subsidiaries and are protected under applicable intellectual property laws. Solely for convenience, LivaNova's trademarks and trade names referred to in this material may appear without the ™ symbol, but such references are not intended to indicate in any way that the Company will not assert, to the fullest extent under applicable law, LivaNova's rights to these trademarks and trade names.

Contents

1Q25 Key Messages and Summary

1Q25 Financial Results

2025 Guidance and Assumptions

Appendix

1Q25 Highlights and Key Messages

Financial Results

- *Delivered high-single-digit revenue growth, **double-digit organic revenue growth, and continued operating margin expansion***

Full-Year 2025 Guidance

- ***Raised full-year 2025 revenue guidance by 100 basis points to 6.0% - 7.0% on a constant-currency basis and 7.0% - 8.0% on an organic basis***
- *Revised full-year **2025 adjusted diluted earnings per share range to \$3.60 - \$3.70** (versus \$3.65 - \$3.75 prior) now **incorporates impact of SNIA decision, currently applicable tariffs, and reflects stronger operational performance***

SNIA Environmental Liability Ruling

- *Recorded a liability €333.3 million (\$360.4 million as of March 31, 2025) as the best estimate of the liability inclusive of estimated costs, fees, interest, and taxes*
- ***Repaid \$200 million of the Term Facilities** on May 2, 2025, which had a principal balance of \$313 million as of March 31, 2025*

Regulatory and Clinical Milestones

- ***Completed premarket approval submission** for the aura6000™ System intended to treat obstructive sleep apnea*
- *Announced **12-month top-line OSPREY data demonstrating strong response and sustained therapeutic impact** for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea*

1Q25 Summary

ORGANIC REVENUE GROWTH ⁽¹⁾	10.4%	<ul style="list-style-type: none"> • Cardiopulmonary growth of 15.0% driven by Essenz™ Perfusion system sales and consumables demand • Neuromodulation growth of 4.7% driven by strength in Europe and Rest of World regions <ul style="list-style-type: none"> ◦ U.S. Epilepsy growth of 2.2% partially impacted by procedure deferrals related to a field safety notification addressed by a design change approved by FDA in 2Q25
ADJUSTED DILUTED EPS ⁽²⁾	\$0.88	<ul style="list-style-type: none"> • Adjusted operating margin favorably impacted by higher revenue, optimization of DTD program spend, and ACS wind down
ADJUSTED FCF ⁽³⁾	\$20M	<ul style="list-style-type: none"> • Adjusted free cash flow favorably impacted by stronger operating results and working capital improvements, and inclusive of short-term incentive bonus payouts in the first quarter (historically paid in the second quarter)
OSA	Clinical and Regulatory Milestones	<ul style="list-style-type: none"> • Announced 12-month, top-line data from the OSPREY trial demonstrating strong response and durability of therapy for patients who received p-HGNS, including those with severe OSA, elevated body mass index, and high risk of complete concentric collapse. At 12-months of therapy: <ul style="list-style-type: none"> ◦ Active patient responder rate was 65% ◦ Median percent reduction of AHI was 68% ◦ Median percent reduction of ODI was 68%
DTD	Critical Article Publications	<ul style="list-style-type: none"> • Continued efforts in pursuit of CMS coverage for VNS Therapy™ for DTD patients, including the publication of two additional critical articles, bringing the total to four. The fifth and final critical publication is expected to be published in 2Q25

FCF: Free cash flow; DTD: Difficult-to-treat depression; OSA: Obstructive sleep apnea; CMS: U.S. Centers for Medicare and Medicaid Services; p-HGNS: Proximal hypoglossal nerve stimulation

Organic revenue growth, adjusted diluted EPS and adjusted FCF are non-GAAP measures. (1) Organic revenue growth excludes the impact of acquisitions, divestitures, and currency translations effects. Foreign currency is expected to be a headwind of 0.0% to 1.0% based on current exchange rates. (2) Adjusted diluted EPS assumes adjusted diluted weighted average shares outstanding of approximately 55 million for the full year of 2025. (3) Adjusted free cash flow is defined as net cash provided by operating activities less cash used for the purchase of property, plant, and equipment excluding the impact of 3T litigation settlement payments, cybersecurity incident insurance proceeds, SNIA environmental liability and related financing costs, and gains related to dividends received from investments and further adjusted as needed for other charges, expenses or gains that may not be indicative of the Company's operational performance.


Financial Results

1Q25 Financial Summary


1Q24 1Q25

Net revenue increased 8.9% on a constant-currency basis and 10.4% on an organic basis; unfavorable FX impact of ~\$4M, or 1%


Net Revenue (\$M)




Adjusted Diluted EPS




Adjusted FCF (\$M)




Adjusted Gross Profit %




Adjusted SG&A %



Adjusted R&D %



Adjusted Operating Margin %



FX: Foreign exchange; FCF: Free cash flow. Note: Constant-currency percent change, organic revenue percent change, adjusted diluted EPS, adjusted FCF as well as adjusted gross profit, adjusted SG&A, adjusted R&D, and adjusted operating margin all as a percentage of net revenue are non-GAAP measures. Constant currency excludes the effects of foreign currency fluctuations as compared to reported percent change, and organic revenue percent change excludes the impact of acquisitions, divestitures, and currency translations effects. For reconciliations of certain non-GAAP metrics, see the tables in the appendix. For additional details, see the 8-K furnished with the SEC on May 7, 2025. Numbers may not add precisely due to rounding.

1Q25 Net Revenue

Delivered double-digit organic revenue growth


Neuromodulation

Vagus Nerve Stimulation Therapy (VNS Therapy)

- Drug-Resistant Epilepsy (DRE)
- Difficult-to-Treat Depression (DTD)

Proximal Hypoglossal Nerve Stimulation Therapy (p-HGNS Therapy)

- Obstructive Sleep Apnea (OSA)



Cardiopulmonary (CP)

- Heart-lung machines (HLM)
- Oxygenators
- Autotransfusion systems (ATS)
- Cannulae

Numbers may not add precisely due to rounding.
Percentages by segment exclude "Other" revenue.


Other revenue primarily includes revenue from the Company's former ACS reportable segment, as well as rental and site services income not allocated to segments.

⁽¹⁾ Percent change performance is shown on a year-over-year organic basis, which is a non-GAAP measure. Organic revenue percent change excludes the impact of acquisitions, divestitures, and currency translations effects. For reconciliations of certain non-GAAP metrics, see the tables in the appendix.

1Q25 Cardiopulmonary Revenue⁽¹⁾

Drivers/Impacts

- Cardiopulmonary revenue increased 15.0% with double-digit growth across all regions.
- Strong global demand for consumables led to high-single-digit growth.
- HLM revenue grew approximately 30% driven by Essenz sales.



Numbers may not add precisely due to rounding.

⁽¹⁾ All percent change performance is shown on a year-over-year constant-currency basis, which is a non-GAAP measure. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. For reconciliations of certain non-GAAP metrics, see the tables in the appendix.

1Q25 Neuromodulation Revenue⁽¹⁾

Drivers/Impacts

Neuromodulation revenue increased 4.7% driven by strength in the Europe and Rest of World regions.

Epilepsy revenue grew 4.4% with U.S. Epilepsy revenue growth of 2.2%.

Europe and Rest of World Epilepsy revenue increased a combined 12.9%.


Net Revenue (\$M)




Numbers may not add precisely due to rounding.

⁽¹⁾ All percent change performance is shown on a year-over-year constant-currency basis, which is a non-GAAP measure. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. For reconciliations of certain non-GAAP metrics, see the tables in the appendix.

1Q25 Adjusted Segment Income and Margin⁽¹⁾



	% to Revenue	
	1Q24	1Q25
Cardiopulmonary	16.1%	16.1%
Neuromodulation	36.2%	39.8%
Total Adjusted Segment Margin	25.4%	26.5%
Total Adjusted Operating Margin⁽²⁾	18.0%	20.4%



Numbers may not add precisely due to rounding. Segment financial information presented herein reflects LivaNova's change in segments, effective in the first quarter 2024, for all periods presented.⁽¹⁾ Adjusted segment income and margin are non-GAAP measures. These non-GAAP measures are reconciled to the most directly comparable GAAP measures in the appendix. For additional details, see the 8-K furnished with the SEC on May 7, 2025.⁽²⁾ Includes other income and expense not allocated to segments primarily including corporate expense, rental income, and the results of LivaNova's former ACS reportable segment.

Adjusted Free Cash Flow

Targeting \$135 - 155M of adjusted free cash flow (FCF) for full-year 2025

Adjusted Free Cash Flow Reconciliation (\$M)	1Q 2024	1Q 2025
Net cash provided by operating activities	\$10.0	\$24.0
Less: Purchases of plant, property, and equipment	(6.4)	(10.8)
Less: Cybersecurity incident insurance proceeds	—	(0.1)
Add: 3T Heater-Cooler litigation payments	0.2	0.5
Add: SNIA financing costs	7.5	6.5
Adjusted free cash flow	\$11.2	\$20.0

Last Twelve Months (LTM) Adjusted Free Cash Flow Conversion Ratio	LTM Ended March 31, 2024	LTM Ended March 31, 2025
LTM adjusted free cash flow	\$87.9	\$171.7
LTM adjusted net income	\$168.7	\$192.4
LTM adjusted free cash flow conversion ratio	52%	89%

Numbers may not add precisely due to rounding. Adjusted Free Cash Flow (FCF), LTM Adjusted FCF, LTM Adjusted Net Income and LTM Adjusted FCF conversion ratio are non-GAAP measures. LivaNova's definition and calculation of Adjusted FCF may not be comparable to similarly titled measures of other companies.

2025 Guidance

2025 Guidance

Raising full-year revenue guidance, updating adjusted diluted EPS to include SNIA impact and currently applicable tariffs, maintaining adjusted FCF

	Prior Guidance As of February 25, 2025	Updated Guidance As of May 7, 2025
Net revenue growth ⁽¹⁾	5.0 - 6.0%	6.0 - 7.0%
Organic net revenue growth ⁽²⁾	6.0 - 7.0%	7.0 - 8.0%
Foreign exchange headwind	1.5 - 2.0%	0.0 - 1.0%
Adjusted diluted EPS ⁽³⁾	\$3.65 - \$3.75 (excludes SNIA impact & tariffs)	\$3.60 - \$3.70 (includes SNIA impact & tariffs)
Adjusted free cash flow ⁽⁴⁾	\$135 - 155M	\$135 - 155M


Net revenue growth on a constant-currency basis, organic net revenue growth, adjusted diluted EPS and adjusted free cash flow are non-GAAP measures. (1) Net revenue growth is on a constant-currency basis. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. (2) Organic net revenue growth excludes the impact of acquisitions, divestitures, and currency translations effects. (3) Adjusted diluted EPS assumes adjusted diluted weighted average shares outstanding of approximately 55 million for the full year of 2025. (4) Adjusted free cash flow is defined as net cash provided by operating activities less cash used for the purchase of property, plant, and equipment excluding the impact of 3T litigation settlement payments, cybersecurity incident insurance proceeds, SNIA environmental liability and related financing costs, and gains related to dividends received from investments and further adjusted as needed for other charges, expenses or gains that may not be indicative of the Company's operational performance.

Assumptions for 2025


ORGANIC REVENUE GROWTH ⁽¹⁾	7.0 - 8.0%	<ul style="list-style-type: none"> • Cardiopulmonary revenue now expected to grow 9.0 - 10.0% (versus 7.0 - 8.0% prior) • Epilepsy revenue growth expected to grow 4.0 - 5.0% (maintained) • DTD revenue expected to be in the range of \$11.5M - \$12.5M, driven by program optimization efforts
ADJUSTED DILUTED EPS ⁽²⁾	\$3.60 - 3.70	<ul style="list-style-type: none"> • Adjusted operating income margin increase of > 190bps and adjusted operating income growth of > 15% • Investing in core innovation and accelerated OSA product development to drive long-term value creation with DTD actions providing operating leverage • EPS growth of 8% at midpoint, despite SNIA impact (~\$0.20) and impact of 300bps step up in effective tax rate (~\$0.12)
ADJUSTED FCF ⁽³⁾	\$135 - 155M	<ul style="list-style-type: none"> • Continued free cash flow generation driven by improving profitability, partially offset by higher capital investment and certain one-time payments • Capital spend of \$90M to support IT infrastructure, innovation, and growth • Continued focus on disciplined working capital management
OSA	Product Development	<ul style="list-style-type: none"> • Continue to progress toward competitive and differentiated product portfolio within p-HGNS platform
DTD	Pursue Reimbursement	<ul style="list-style-type: none"> • Continue efforts in pursuit of CMS coverage for VNS Therapy™ for difficult-to-treat depression patients with reduced investment in 2025

BPS: Basis points; FCF: Free cash flow; DTD: Difficult-to-treat depression; OSA: Obstructive sleep apnea; CMS: U.S. Centers for Medicare and Medicaid Services; p-HGNS: Proximal hypoglossal nerve stimulation
 Organic revenue growth, adjusted diluted EPS and adjusted FCF are non-GAAP measures. (1) Organic revenue growth excludes the impact of acquisitions, divestitures, and currency translations effects. Foreign currency is expected to be a headwind of 0.0% to 1.0% based on current exchange rates. (2) Adjusted diluted EPS assumes adjusted diluted weighted average shares outstanding of approximately 55 million for the full year of 2025. (3) Adjusted free cash flow is defined as net cash provided by operating activities less cash used for the purchase of property, plant, and equipment excluding the impact of 3T litigation settlement payments, cybersecurity incident insurance proceeds, SNIA environmental liability and related financing costs, and gains related to dividends received from investments and further adjusted as needed for other charges, expenses or gains that may not be indicative of the Company's operational performance.

RECOVER Manuscript Publication Timeline



Adjusted Diluted EPS⁽¹⁾ Guidance Bridge: From Initial to Current Outlook



⁽¹⁾Adjusted diluted EPS is a non-GAAP measure. This non-GAAP measure is reconciled to its GAAP measure in the appendix. ⁽²⁾Includes the Company's current and best estimate of the potential impact of presently applicable tariffs.

Appendix

GAAP to Non-GAAP Reconciliations

To supplement financial measures presented in accordance with generally accepted accounting principles in the United States (U.S. GAAP or GAAP), management has disclosed certain additional measures not presented in accordance with GAAP known as “non-GAAP financial measures” or “adjusted financial measures.” Company management uses these non-GAAP measures to monitor the Company’s operational performance and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, operational performance measures as prescribed by GAAP.

In this material, the Company refers to revenue and percentage change in revenue on a comparable, constant-currency, and organic basis. Company management believes that these non-GAAP measures provide a useful way to evaluate the revenue performance of LivaNova and to compare the revenue performance of current periods to prior periods on a consistent basis. Constant-currency percent change measures the change in revenue between current and prior-year periods using average exchange rates in effect during the applicable prior-year period. Organic revenue percent change excludes the impact of acquisitions, divestitures, and currency translation effects.

LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net revenue growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per share guidance exclude items such as, but not limited to, changes in fair value of derivatives and contingent consideration arrangements and asset impairment charges that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for adjusted free cash flow is net cash provided by operating activities. Adjusted free cash flow is defined as net cash provided by operating activities less cash used for the purchase of property, plant, and equipment excluding the impact of 3T litigation settlement payments, cybersecurity incident insurance proceeds, SNIA environmental liability and related financing costs, and gains related to dividends received from investments and further adjusted as needed for other charges, expenses or gains that may not be indicative of the Company’s operational performance. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, the ultimate outcome of legal proceedings, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of derivatives, and contingent consideration arrangements, asset impairment charges and the tax impact of the aforementioned items, tax law changes, or other tax matters. Accordingly, the Company does not reconcile non-GAAP financial measures on a forward-looking basis as it is impractical to do so without unreasonable effort.

Adjusted financial measures such as organic revenue, adjusted cost of sales, adjusted gross profit, adjusted selling, general, and administrative expense, adjusted research and development expense, adjusted other operating expenses, adjusted operating income, adjusted income before tax, adjusted income tax expense, adjusted net income, and adjusted diluted earnings per share, are measures that LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning, and in the design of incentive compensation plans. Additionally, the Company uses the non-GAAP liquidity measure adjusted free cash flow. The Company believes that the presentation of these adjusted financial measures allows investors to evaluate the Company’s operational performance for different periods on a more comparable and consistent basis, and with other medical technology companies by adjusting for items that are not related to the operational performance of the Company or incurred in the ordinary course of business.

Segment Net Revenue Comparisons by Region

(\$M)	Three Months Ended March 31,		% Change	Constant-Currency % Change ⁽¹⁾
	2025	2024		
Cardiopulmonary				
United States	\$60.8	\$50.6	20.3%	20.3%
Europe ⁽²⁾	44.5	40.9	8.7%	11.0%
Rest of World	71.0	64.4	10.2%	13.4%
	176.3	155.9	13.1%	15.0%
Neuromodulation				
United States	108.3	105.9	2.3%	2.3%
Europe ⁽²⁾	15.2	13.4	13.3%	15.9%
Rest of World	15.4	14.5	5.7%	11.7%
	138.9	133.9	3.8%	4.7%
Other Revenue ⁽³⁾	1.6	5.1	(68.1)%	(67.2)%
Total Net Revenue	\$316.9	\$294.9	7.4%	8.9%
Less: ACS ⁽⁴⁾	—	4.1	(100.0)%	(100.0)%
Total Net Revenue, Excluding ACS⁽¹⁾	\$316.9	\$290.8	N/A	10.4%

Numbers may not add precisely due to rounding. Segment financial information presented herein reflects LivaNova's change in segments, effective in the first quarter 2024, for all periods presented. ACS: Advanced Circulatory Support.

⁽¹⁾ Constant-currency percent change, organic net revenue, and organic revenue percent change are non-GAAP measures. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. Organic revenue percent change excludes the impact of acquisitions, divestitures, and currency translations effects. Organic net revenue excludes the impact of acquisitions and divestitures. For reconciliations of certain non-GAAP metrics, see the tables in the appendix. ⁽²⁾ "Europe" includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., "Rest of World" includes all other countries where LivaNova operates. ⁽³⁾ "Other Revenue" includes rental and site services income not allocated to segments. In addition, "Other Revenue" for the three months ended March 31, 2024 includes revenue from the Company's former ACS reportable segment (4) Includes the results from the wind down portion of the Company's former ACS reportable segment.

GAAP to Non-GAAP Reconciliations - Unaudited

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(US dollars in millions, except per share amounts)

Three Months Ended March 31, 2025	Specified Items									Adjusted Financial Measures
	GAAP Financial Measures	Restructuring Expenses ⁽¹⁾	Depreciation and Amortization Expenses ⁽²⁾	Financing Transactions ⁽³⁾	Contingent Consideration ⁽⁴⁾	Certain Legal & Regulatory Costs ⁽⁵⁾	Stock-based Compensation Costs ⁽⁶⁾	Certain Tax Adjustments ⁽⁷⁾	Certain Interest Adjustments ⁽⁸⁾	
Cost of sales	\$96.1	\$—	\$(1.7)	\$—	\$(0.3)	\$—	\$(0.2)	\$—	\$—	\$94.0
Gross profit percent	69.7 %	— %	0.5 %	— %	0.1 %	— %	0.1 %	— %	— %	70.3 %
Selling, general, and administrative	133.7	—	(2.5)	—	—	(4.6)	(6.5)	—	—	120.2
Selling, general, and administrative as a percent of net revenue	42.2 %	— %	(0.8)%	— %	— %	(1.4)%	(2.0)%	— %	— %	37.9 %
Research and development	37.9	—	0.1	—	(0.7)	2.0	(1.2)	—	—	38.2
Research and development as a percent of net revenue	12.0 %	— %	— %	— %	(0.2)%	0.6 %	(0.4)%	— %	— %	12.0 %
Other operating expense	0.6	0.1	—	—	—	(0.7)	—	—	—	—
Operating income	48.6	(0.1)	4.1	—	0.9	3.2	7.8	—	—	64.6
Operating margin percent	15.3 %	— %	1.3 %	— %	0.3 %	1.0 %	2.5 %	— %	— %	20.4 %
Net (loss) income	(327.3)	(0.1)	4.1	(5.7)	0.9	363.6	7.8	(3.7)	8.4	48.1
Net (loss) income as a percent of net revenue	(103.3)%	— %	1.3 %	(1.8)%	0.3 %	114.8 %	2.5 %	(1.2)%	2.7 %	15.2 %
Diluted EPS	\$(6.01)	\$0.00	\$0.07	\$(0.10)	\$0.02	\$6.65	\$0.14	\$(0.07)	\$0.15	\$0.88

GAAP results for the three months ended March 31, 2025 include:

- (1) Restructuring expenses related to organizational changes
- (2) Depreciation and amortization associated with purchase price accounting
- (3) Mark-to-market adjustments for the 2025 & 2029 Notes embedded and capped call derivatives
- (4) Remeasurement of contingent consideration related to the ImThera acquisition
- (5) SNIA environmental liability, legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater-Cooler litigation provision, cybersecurity incident costs net of insurance reimbursement, Medical Device Regulation ("MDR") costs, and R&D tax incentive
- (6) Non-cash expenses associated with stock-based compensation costs
- (7) The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments
- (8) Interest expense on the Term Facilities, non-cash interest expense on the 2025 & 2029 Notes and Revolving Credit Facility, and interest income on the collateral for the SNIA litigation guarantee and delayed draw on Term Facilities

- Numbers may not add precisely due to rounding.

GAAP to Non-GAAP Reconciliations - *Unaudited*

(US dollars in millions, except per share amounts)

Three Months Ended March 31, 2024	Specified Items									Adjusted Financial Measures
	GAAP Financial Measures	Restructuring Expenses ⁽¹⁾	Depreciation and Amortization Expenses ⁽²⁾	Financing Transactions ⁽³⁾	Contingent Consideration ⁽⁴⁾	Certain Legal & Regulatory Costs ⁽⁵⁾	Stock-based Compensation Costs ⁽⁶⁾	Certain Tax Adjustments ⁽⁷⁾	Certain Interest Adjustments ⁽⁸⁾	
Cost of sales	\$87.5	\$—	\$(1.7)	\$—	\$0.2	\$—	\$(0.4)	\$—	\$—	\$85.6
Gross profit percent	70.3 %	— %	0.6 %	— %	(0.1)%	— %	0.1 %	— %	— %	71.0 %
Selling, general, and administrative	129.9	—	(2.6)	—	—	(6.1)	(7.8)	—	—	113.3
Selling, general, and administrative as a percent of net revenue	44.0 %	— %	(0.9)%	— %	— %	(2.1)%	(2.7)%	— %	— %	38.4 %
Research and development	45.7	—	—	—	—	(0.8)	(2.0)	—	—	42.9
Research and development as a percent of net revenue	15.5 %	— %	— %	— %	— %	(0.3)%	(0.7)%	— %	— %	14.5 %
Other operating expense	15.6	(9.2)	—	—	—	(6.4)	—	—	—	—
Operating income	16.2	9.2	4.3	—	(0.1)	13.2	10.2	—	—	53.1
Operating margin percent	5.5 %	3.1 %	1.5 %	— %	— %	4.5 %	3.5 %	— %	— %	18.0 %
Net (loss) income	(41.9)	9.2	4.3	40.3	(0.1)	13.2	10.2	(2.8)	7.6	40.0
Net (loss) income as a percent of net revenue	(14.2)%	3.1 %	1.5 %	13.7 %	— %	4.5 %	3.5 %	(1.0)%	2.6 %	13.6 %
Diluted EPS	\$(0.78)	\$0.17	\$0.08	\$0.74	\$—	\$0.24	\$0.19	\$(0.05)	\$0.14	\$0.73

GAAP results for the three months ended March 31, 2024 include:

- (1) Restructuring expenses related to organizational changes
- (2) Depreciation and amortization associated with purchase price accounting
- (3) Loss on debt extinguishment, as well as mark-to-market adjustments for the 2025 & 2029 Notes embedded and capped call derivatives
- (4) Remeasurement of contingent consideration related to the ImThera acquisition
- (5) 3T Heater-Cooler litigation provision, cybersecurity incident costs, legal expenses primarily related to 3T Heater-Cooler defense, costs related to the SNIA matter, and MDR costs
- (6) Non-cash expenses associated with stock-based compensation costs
- (7) The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments
- (8) Interest expense on the Term Facilities, non-cash interest expense on the 2025 and 2029 Notes and Revolving Credit Facility, and interest income on the collateral for the SNIA litigation guarantee and delayed draw on Term Facilities

- Numbers may not add precisely due to rounding.

GAAP to Non-GAAP Reconciliations - Unaudited

UNAUDITED
(U.S. dollars in millions)

Adjusted free cash flow reconciliation	Three Months Ended March 31,	
	2025	2024
Net cash provided by operating activities	\$24.0	\$10.0
Less: Purchases of plant, property, and equipment	(10.8)	(6.4)
Less: Cybersecurity incident insurance proceeds	(0.1)	—
Add: 3T Heater-Cooler litigation payments	0.5	0.2
Add: SNIA financing costs	6.5	7.5
Adjusted free cash flow	<u>\$20.0</u>	<u>\$11.2</u>

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions)

Net debt reconciliation	March 31, 2025
Total long-term debt	\$628.2
Add: Short-term debt	0.6
Total debt	628.8
Less: Carrying value of 2029 Notes	(262.2)
Add: Nominal value of 2029 Notes	345.0
Less: Carrying value of 2025 Notes	(54.8)
Add: Nominal value of 2025 Notes	57.5
Less: Carrying value of Term Facilities	(309.1)
Add: Nominal value of Term Facilities	313.4
Less: Cash and cash equivalents	(738.4)
Net debt	<u><u>\$(19.8)</u></u>

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions)

Adjusted free cash flow reconciliation	Twelve Months Ended March 31,	
	2025	2024
Net cash provided by operating activities	\$197.0	\$64.1
Less: Purchases of plant, property, and equipment	(51.5)	(33.7)
Less: Dividends received from investments	—	(1.5)
Less: Cybersecurity incident insurance proceeds	(5.2)	—
Add: 3T Heater-Cooler litigation payments	17.7	42.2
Add: SNIA financing costs	13.7	16.8
Adjusted free cash flow	<u>\$171.7</u>	<u>\$87.9</u>

Adjusted net income reconciliation

Net loss	\$(222.1)	\$(31.8)
Merger & integration expenses	—	(0.2)
Restructuring expenses	4.0	9.5
Depreciation and amortization expenses	16.9	23.9
Impairment	5.8	102.6
Financing transactions	(47.8)	37.1
Contingent Consideration	4.4	4.4
Gain and Dividend	392.8	67.8
Stock-based compensation costs	31.5	36.0
Certain tax adjustments	(24.9)	(111.7)
Certain interest adjustments	31.9	31.1
Adjusted net income	<u>\$192.4</u>	<u>\$168.7</u>

Last twelve months free cash flow conversion ratio

GAAP	(89)%	(202)%
Adjusted	89 %	52 %

GAAP to Non-GAAP Reconciliation - Unaudited

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions)

Segment income Three Months Ended March 31, 2025	Specified Items					Adjusted Financial Results	% to Revenue
	GAAP Financial Results	Contingent Consideration ⁽¹⁾	Certain Legal & Regulatory Costs ⁽²⁾	Stock-based Compensation Costs ⁽³⁾			
Cardiopulmonary	\$24.7	\$—	\$2.5	\$1.2		\$28.4	16.1 %
Neuromodulation	52.4	0.9	—	2.0		55.2	39.8 %

Segment income Three Months Ended March 31, 2024	Specified Items					Adjusted Financial Results	% to Revenue
	GAAP Financial Results	Contingent Consideration ⁽¹⁾	Certain Legal & Regulatory Costs ⁽²⁾	Stock-based Compensation Costs ⁽³⁾			
Cardiopulmonary	\$14.7	\$—	\$9.4	\$1.1		\$25.2	16.1 %
Neuromodulation	46.7	(0.1)	—	1.9		48.5	36.2 %

GAAP results for the three months ended March 31, 2025 and 2024 include:

- ⁽¹⁾ Remeasurement of contingent consideration related to the ImThera acquisition
- ⁽²⁾ Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater-Cooler litigation provision, MDR costs, and R&D tax incentive
- ⁽³⁾ Non-cash expenses associated with stock-based compensation costs
- Numbers may not add precisely due to rounding.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED
(U.S. dollars in millions)

	Three Months Ended March 31,		% Change	Constant-Currency % Change
	2025	2024		
GAAP net revenue	\$316.9	\$294.9	7.4 %	8.9 %
Less: ACS ⁽¹⁾	—	4.1	(100.0)%	(100.0)%
Organic net revenue	<u>\$316.9</u>	<u>\$290.8</u>	N/A	10.4 %

- ⁽¹⁾ Includes net revenue from the Company's former ACS reportable segment.
- Numbers may not add precisely due to rounding.